Inhibitory CARs fail to protect from immediate T cell cytotoxicity
2024年4月3日 · Chimeric antigen receptors (CARs) equipped with an inhibitory signaling domain (iCARs) have been proposed as strategy to increase on-tumor specificity of CAR-T cell therapies. iCARs inhibit T cell activation upon antigen recognition and thereby program a Boolean NOT gate within the CAR-T cell.
Development of Intelligent Chimeric Antigen Receptor (iCAR) T-Cells …
2024年11月5日 · Chimeric antigen receptor T cell therapies (CAR-Ts) are regarded as one of the most promising immunotherapies for patients with hematological malignancies and continue to be a major focus of research, with almost 1,000 clinical trials actively recruiting patients.
Modified Dual CLL1-CD15 and CLL1-CD16 Icar-T Cells for …
2024年11月5日 · CLL1 Chimeric antigen receptor T-cell (CAR-T) therapy, as a promising immunotherapeutic approach, has demonstrated its potential to enhance the prognosis of patients diagnosed with acute myeloid leukemia (AML).
Development of Intelligent Chimeric Antigen Receptor (iCAR) T-Cells …
2024年11月5日 · Chimeric antigen receptor T cell therapies (CAR-Ts) are regarded as one of the most promising immunotherapies for patients with hematological malignancies and continue to be a major focus of research, with almost 1,000 clinical trials actively recruiting patients.
Dual-inhibitory domain iCARs improve the efficiency of the AND …
2023年11月21日 · Using a TROP2-targeting iCAR with a single PD1 inhibitory domain to inhibit a CEACAM5-targeting CAR (CEACAR), we observed that the inefficiency was due to a kinetic delay in iCAR inhibition of cytotoxicity. To improve iCAR efficiency, we modified three features of the iCAR-the avidity, the affinity, and the intracellular signaling domains.
Inhibitory Chimeric Antigen Receptors That Reduce Car-T Cell “On …
Researchers at UCLA lead by Dr. Owen Witte have improved the inhibitory kinetics of CAR-T cell therapy by designing a novel dual-signaling inhibitory CAR (iCAR) system. The research team screened a panel of iCAR constructs composed of intracellular inhibitory domains fused to existing CAR framework necessary for antigen recognition previously ...
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic
2023年12月14日 · Here, we describe a dual CAR NOT gate incorporating an inhibitory CAR (iCAR) recognizing HLA-A*02 ("A2") that enables effective treatment with a potent HER2 activating CAR (aCAR) in the context of A2 loss of heterozygosity (LOH).
Chimeric antigen receptor with novel intracellular modules …
2025年1月15日 · The excessive cytokine release and limited persistence represent major challenges for chimeric antigen receptor T (CAR-T) cell therapy in diverse tumors. Conventional CARs employ an intracellular ...
Inhibitory CARs fail to protect from immediate T cell cytotoxicity
2024年2月22日 · Chimeric antigen receptors (CARs) equipped with an inhibitory signaling domain (iCARs) have been proposed as strategy to increase on-tumor specificity of CAR-T cell therapies. iCARs inhibit T cell activation upon antigen recognition and thereby program a Boolean NOT gate within the CAR-T cell.
Unraveling barriers to iPSC-derived CAR-T cell differentiation - Cell …
2023年3月2日 · Merging induced pluripotent stem cell (iPSC) and Chimeric Antigen Receptor (CAR) technologies can potentially afford an unlimited source of “off-the-shelf” T lymphocytes targeted to a range of chosen antigens independent of HLA restriction and thus create a universally accessible approach to cancer immunotherapy.
- 某些结果已被删除